Lois E. Krahn
YOU?
Author Swipe
View article: Narcolepsy and cardiovascular health: A big picture perspective
Narcolepsy and cardiovascular health: A big picture perspective Open
Narcolepsy is an uncommon, chronic neurologic disorder characterized by pervasive excessive daytime sleepiness (EDS) that can occur with cataplexy (narcolepsy type 1) or without cataplexy (narcolepsy type 2). People with narcolepsy have an…
View article: 0689 Exploratory Study of the Effect of Alcohol on Home Sleep Apnea Testing Utilizing Peripheral Arterial Tone
0689 Exploratory Study of the Effect of Alcohol on Home Sleep Apnea Testing Utilizing Peripheral Arterial Tone Open
Introduction A previously published case report suggested that alcohol might cause false-negative results in home sleep apnea testing (HSAT) utilizing Peripheral Arterial Tonometry (PAT). Alcohol is consumed by nearly a third of people glo…
View article: 0828 Impact of AXS-12 on Symptom Severity and Functional Impairment in Narcolepsy: Results from the Phase 3 SYMPHONY Trial
0828 Impact of AXS-12 on Symptom Severity and Functional Impairment in Narcolepsy: Results from the Phase 3 SYMPHONY Trial Open
Introduction Narcolepsy is a chronic neurologic condition associated with severe symptom burden, impaired functioning and reduced quality of life. Patients commonly report comorbid mood disorders. AXS-12 (reboxetine) is a selective norepin…
View article: 0843 ENCORE: Topline Results of a Phase 3 Open-Label Extension and Randomized-Withdrawal Trial of AXS-12 in Narcolepsy
0843 ENCORE: Topline Results of a Phase 3 Open-Label Extension and Randomized-Withdrawal Trial of AXS-12 in Narcolepsy Open
Introduction AXS-12 (reboxetine) is a highly selective norepinephrine reuptake inhibitor and cortical dopamine modulator under development for narcolepsy. In the Phase 3 SYMPHONY trial, AXS-12 significantly reduced weekly cataplexy attacks…
View article: Characterization and treatment patterns of patients treated with immediate-release sodium oxybate for narcolepsy: A propensity score–matched cohort study
Characterization and treatment patterns of patients treated with immediate-release sodium oxybate for narcolepsy: A propensity score–matched cohort study Open
No significant differences in comorbidities were observed between cohorts. Although SXB is a highly effective treatment for narcolepsy, this study highlights challenges patients face while taking twice-nightly SXB, which may result in unde…
View article: Assessing Early Efficacy After Initiation of Once-Nightly Sodium Oxybate (ON-SXB; FT218) in Participants with Narcolepsy Type 1 or 2: A Post Hoc Analysis from the Phase 3 REST-ON Trial
Assessing Early Efficacy After Initiation of Once-Nightly Sodium Oxybate (ON-SXB; FT218) in Participants with Narcolepsy Type 1 or 2: A Post Hoc Analysis from the Phase 3 REST-ON Trial Open
NCT02720744.
View article: Clinical considerations in the treatment of idiopathic hypersomnia
Clinical considerations in the treatment of idiopathic hypersomnia Open
Idiopathic hypersomnia typically is a chronic and potentially debilitating neurologic sleep disorder, and is characterized by excessive daytime sleepiness. In addition to excessive daytime sleepiness, idiopathic hypersomnia symptoms can in…
View article: 0657 Understanding the Debilitating Nature of Narcolepsy in Patients’ Own Words: A Social Listening Analysis
0657 Understanding the Debilitating Nature of Narcolepsy in Patients’ Own Words: A Social Listening Analysis Open
Introduction To further characterize the many struggles and unmet needs of people with narcolepsy (PWN), passive social listening was used to explore how PWN describe the condition using their own words. Methods MyNarcolepsyTeam is a socia…
View article: 0576 Characterization of Patients With Narcolepsy Treated vs Not Treated With Sodium Oxybate: A Propensity Score–Matched Cohort Study
0576 Characterization of Patients With Narcolepsy Treated vs Not Treated With Sodium Oxybate: A Propensity Score–Matched Cohort Study Open
Introduction Narcolepsy is a chronic sleep disorder with multiple comorbid conditions. Sodium oxybate (SXB) is strongly recommended for treatment of narcolepsy. This study used aggregate electronic health record (EHR) data to characterize …
View article: 0612 Understanding Narcolepsy Treatments From the Patient’s Perspective: A Survey of People Living With Narcolepsy
0612 Understanding Narcolepsy Treatments From the Patient’s Perspective: A Survey of People Living With Narcolepsy Open
Introduction Individuals with narcolepsy were surveyed to better understand desired treatment outcomes and how those outcomes map to commonly experienced symptoms, treatment awareness, and medication usage. Methods In February 2022, an ema…
View article: 0597 Path to Diagnosis and Impact of Narcolepsy on Quality of Life: A Survey of People Living With Narcolepsy
0597 Path to Diagnosis and Impact of Narcolepsy on Quality of Life: A Survey of People Living With Narcolepsy Open
Introduction Research was undertaken to better understand the path to a narcolepsy diagnosis, common symptoms, and the impact of narcolepsy on work, social interactions, and mental health. Methods In February 2022, an email invitation to a…
View article: 0584 Sodium Oxybate Treatment Patterns in Narcolepsy Patients: A Propensity Score–Matched Cohort Study Subanalysis
0584 Sodium Oxybate Treatment Patterns in Narcolepsy Patients: A Propensity Score–Matched Cohort Study Subanalysis Open
Introduction Sodium oxybate (SXB) is strongly recommended for treatment of narcolepsy. Patients treated with available immediate-release oxybates are required to awaken for a second dose 2.5–4 hours after the bedtime dose to cover a full n…
View article: 0407 Early Efficacy With Once-Nightly Sodium Oxybate (ON-SXB; FT218): Post-hoc Analyses From REST-ON
0407 Early Efficacy With Once-Nightly Sodium Oxybate (ON-SXB; FT218): Post-hoc Analyses From REST-ON Open
Introduction Extended-release once-nightly sodium oxybate (ON-SXB; FT218) is in development for adults with narcolepsy. In REST-ON, significant improvements on the Maintenance of Wakefulness test, Clinical Global Impression of Improvement …
View article: 0789 Mask Magnets May Interact with Pacemakers and Implantable Cardioverter-Defibrillators
0789 Mask Magnets May Interact with Pacemakers and Implantable Cardioverter-Defibrillators Open
Introduction Placing a magnet over a Permanent Pacemaker (PPM) or Implanted Cardioverter-Defibrillator (ICD) may cause the device to pace asynchronously or inhibit tachyarrhythmia detection, respectively, potentially preventing delivery of…
View article: 0405 Patient and Healthcare Provider Surveys of Narcolepsy Disease Burden and Oxybate Treatment Experience
0405 Patient and Healthcare Provider Surveys of Narcolepsy Disease Burden and Oxybate Treatment Experience Open
Introduction Immediate-release sodium oxybate (SXB) and mixed-salt oxybates require patients with narcolepsy to take a second nightly dose 2.5–4 h after the first. Extended-release, once-nightly SXB (ON-SXB; FT218) is an investigational tr…
View article: 0404 Patient and Provider Preferences for Oxybate Treatment for Narcolepsy: A Discrete Choice Experiment
0404 Patient and Provider Preferences for Oxybate Treatment for Narcolepsy: A Discrete Choice Experiment Open
Introduction Currently available immediate-release sodium oxybate (SXB) and mixed-salt oxybates are dosed twice nightly (second 2.5–4 hours after first). Extended-release, once-nightly SXB (ON-SXB; FT218) is in development. To characterize…
View article: 0384 Clinical Utilization of a CSF Orexin Test: First Two Years of Data from Mayo Clinic
0384 Clinical Utilization of a CSF Orexin Test: First Two Years of Data from Mayo Clinic Open
Introduction Orexin deficiency in cerebrospinal fluid (CSF) was first reported in human narcolepsy in 2001, included in diagnostic criteria for narcolepsy in 2014, and made clinically available at the Mayo Clinic in 2019. The purpose of th…
View article: Efficacy of pitolisant in patients with high burden of narcolepsy symptoms: pooled analysis of short-term, placebo-controlled studies
Efficacy of pitolisant in patients with high burden of narcolepsy symptoms: pooled analysis of short-term, placebo-controlled studies Open
Pitolisant, at once-daily doses up to 35.6 mg, was efficacious for reducing excessive daytime sleepiness and cataplexy in patients with severe narcolepsy symptom burden.
View article: 0799 A Population-based Study of Adult Patients With Recurrent, Clinician Diagnosed Sleepwalking and/or Sleep Related Eating Disorder
0799 A Population-based Study of Adult Patients With Recurrent, Clinician Diagnosed Sleepwalking and/or Sleep Related Eating Disorder Open
Introduction The ICSD-3 describes NREM-related parasomnias as abnormal sleep related complex movements where motor behavior occurs in the setting of absent or very minimal higher cognitive function. A population-based twin study reported t…
View article: 0762 Efficacy Of Pitolisant In Patients With High Burden Of Narcolepsy Symptoms
0762 Efficacy Of Pitolisant In Patients With High Burden Of Narcolepsy Symptoms Open
Introduction Recent literature suggests that histamine may play an important role in narcolepsy. This post hoc analysis evaluates the efficacy of pitolisant, a histamine 3 (H3)-receptor antagonist/inverse agonist, in patients with high bur…
View article: Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial
Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial Open
Rationale: Primary treatment of obstructive sleep apnea can be accompanied by a persistence of excessive sleepiness despite adherence. Furthermore, effectiveness of sleep apnea treatment is limited by poor adherence. Currently available ph…